{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"MRD\\[-\\]CR at the 12 months landmark was defined as achievement of CR (including sCR or better) per IMWG-URC by IRC and MRD\\[-\\] status at a sensitivity of 10\\^-5 using NGS based method in the bone marrow at the 12 months landmark (from 8 months to 13 months window). Maintaining MRD\\[-\\]CR for at least 12 months (- 4 weeks) was considered as sustained.","groups":[{"description":"Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study.\n\nDexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study.\n\nPomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.","id":"OG000","title":"Carfilzomib With Pomalidomide and Dexamethasone (KPd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set included all participants who received at least 1 dose of carfilzomib.","reportingStatus":"POSTED","timeFrame":"Day 1 cycle 1 to month 12 (8 to 13 month window)","title":"Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC","type":"SECONDARY","unitOfMeasure":"Participants"}